In order to prevent children morbidity and mortality 116 children aged from 6 months to 5 years from 2 risk groups (1 -with bronchialpulmonary dysplasia and 2 -with congenital heart defects) were vaccinated with pneumococcal 7-valent conjugated vaccine in 2011 at the expense of municipal budget. Among 116 children from both groups 16 (14%) have had community-acquired pneumonia, which is 22 times higher than in general children population in this region. Dynamic 1-year follow-up showed significant decrease of community-acquired pneumonia prevalence in risk groups: from 16/116 (14%) to 1/75 (1%) (p = 0,006). There were no cases of invasive pneumococcal infections among vaccinated children and in 87,5% of them the general morbidity decreased. The frequency of moderate general post-vaccinal reactions was 1,8%, topical reactions -0,9%. There were no other side effects during post-vaccinal period. Thereafter, the vaccination against pneumococcal infection performed in Novosibirsk in children with risk of fatal complications showed high efficacy and safety of the used vaccine.

The article presents the results of the analysis of the main trends in the epidemic process for mycoplasmal and chlamydial infections among children with respiratory diseases over several seasons from November 2018 to July 2020 based on the results of testing 617 serum samples. The data obtained indicate that, along with seasonal fluctuations in seropositivity, there is an epidemiological season from December 2019 to January 2020, characterized by a peak increase in the number of seropositive cases, the largest number of which was detected among school-age children hospitalized for community-acquired pneumonia.

Эффективность монтелукаста натрия в терапии различных фенотипов бронхиальной астмы у детейНовосибирский государственный медицинский университет, кафедра педиатрии: 630091, Новосибирск, Красный пр т, 52 N.V.Kukhtinova, E.G.Kondyurina Efficacy of sodium montelukast in treatment of childhood asthma of various phenotypes SummaryEffects of 12 week course of sodium montelukast (Singular) on lung function, bronchial hyperresponsiveness and markers of eosinophilic inflam mation have been analyzed in children with atopic and non atopic asthma and recurrent bronchitis with allergic rhinitis. The study involved 69 chil dren aged 3 to 16 years. The study results showed that sodium montelukast significantly decreased lung hyperinflation and obstructive ventilatory disorders, recovered bronchial receptor sensitivity and controlled the eosinophilic inflammation. The effect was the most significant in children with non atopic asthma including the complete normalization of lung function. Key words: children, bronchial asthma, obstructive bronchitis, treatment, sodium montelukast. РезюмеБыло проанализировано влияние 12 недельного курса приема монтелукаста натрия (Сингуляра) на параметры внешнего дыхания, показатели бронхиальной реактивности и маркеры эозинофильного воспаления у детей с атопической и неатопической астмой и повторным эпизодом бронхита, сочетающегося с аллергическим ринитом. В исследование были включены 69 детей в возрасте от 3 до 16 лет. Результаты исследования продемонстрировали, что монтелукаст натрия достоверно уменьшает гипервоздушность легочной ткани, устраняет обструктивный вентиляционный дефект, восстанавливает чувствительность рецепторного аппарата бронхов и конт ролирует активность эозинофильного воспаления. У детей с неатопической формой астмы положительное влияние на исследуемые параметры было максимальным, включая полное восстановление вентилируемых объемов. Ключевые слова: дети, бронхиальная астма, обструктивный бронхит, лечение, монтелукаст натрия.

No abstract